Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...

Picture writing the numbers 1 to 5 in a horizontal line, from smallest to largest. Where did you put 1? If you placed 1 on ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...